Glemanserin

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Glemanserin
Glemanserin structure.png
Systematic (IUPAC) name
α-phenyl-1-(2-phenylethyl)-4-piperidine methanol
Clinical data
Legal status ?
Identifiers
CAS number 132553-86-7
ATC code None
PubChem CID 71781
ChemSpider 64815
Chemical data
Formula C20H25NO 
Mol. mass 295.419 g/mol

Glemanserin (INN; MDL-11,939) is a drug which acts as a potent and selective 5-HT2A receptor antagonist.[1] The first truly selective 5-HT2A ligand to be discovered, glemanserin resulted in the development of the widely used and even more potent and selective 5-HT2A receptor antagonist volinanserin (MDL-100,907), which is a fluorinated analogue.[2] Though it was largely superseded in scientific research by volinanserin, glemanserin was investigated clinically for the treatment of generalized anxiety disorder.[3] However, it was ultimately found to be ineffective and was not marketed.[3]

See also[edit]

References[edit]

  1. ^ Mark W. Dudley, Norbert L. Wiech, Francis P. Miller, et al. (1988). "Pharmacological effects of MDL 11,939: A selective, centrally acting antagonist of 5-HT2 receptors". Drug Development Research 13 (1): 29–43. doi:10.1002/ddr.430130104. 
  2. ^ Berend Olivier (10 July 1997). Serotonin Receptors and Their Ligands. Elsevier. p. 167. ISBN 978-0-444-82041-9. Retrieved 6 May 2012. 
  3. ^ a b Sramek JJ, Robinson RE, Suri A, Cutler NR (February 1995). "Efficacy trial of the 5-HT2 antagonist MDL 11,939 in patients with generalized anxiety disorder". Journal of Clinical Psychopharmacology 15 (1): 20–2. doi:10.1097/00004714-199502000-00004. PMID 7714223.